Healthy and primary open-angle glaucoma individuals were enrolled in this observational, cross-sectional study. The Ethics Committee of the Federal University of Sao Paulo approved the study protocol. The research followed the tenets of the Declaration of Helsinki. All participants provided informed consent.
All patients underwent complete ophthalmic examinations, including best-corrected visual acuity measurement, slit-lamp biomicroscopy, gonioscopy, Goldmann tonometry, dilated fundus biomicroscopy, stereophotography, 24-2 SAP (Humphrey Visual Field Analyzer, Carl Zeiss Meditec, Dublin, CA, USA), and 24-2 FDT matrix (Carl Zeiss Meditec) perimetries. Clinical exams were performed within 6 months for healthy subjects and within 3 months for glaucoma patients. Both eyes were examined in each subject. If both eyes met the eligibility criteria, one eye per subject was selected randomly to be included in the study.
All healthy individuals and glaucoma patients must have had the following measurements: refractive error between ±6.00 spherical diopters and ±3.00 cylindrical diopters, and absence of macular changes or any other significant retinal disease that could interfere with the exams. All glaucoma patients were under treatment and had an IOP of <20 mm Hg. The healthy subjects had a best-corrected visual acuity of 20/40 or better, a normal optic disc, and a normal 24-2 SAP.
In addition, glaucoma patients must have had previous experience with SAP in at least two exams, a best-corrected visual acuity of 20/200 or better, signs of glaucomatous optic neuropathy, and an abnormal 24-2 SAP. Glaucomatous optic neuropathy was defined as the presence of either cup/disc asymmetry of >0.2 between the two eyes that was unexplained by asymmetry in disc size, rim thinning, peripapillary hemorrhage, or an RNFL defect.
An abnormal visual field was defined as the presence of at least one of the following criteria: Glaucoma Hemifield Test outside the normal limits, pattern standard deviation with a probability level of <5%, or a visual field defect on the pattern deviation chart. For SAP, a group of at least three adjacent points with a probability level of <5%, with 1 point having a probability level of <1%, was considered a visual field defect. The FDT matrix perimetry defect was defined by the presence of at least one point with a probability level of <1%. The visual field change was confirmed by at least one test.
The following exclusion criteria were applied: the presence of mean opacities that precluded the performance of study exams or unreliable perimetry, as defined by excessive false-positive (>10%), false-negative, or fixation loss (>20%) rates; glaucoma suspects; and patients with ocular hypertension.
20